AbbVie has agreed with iSTAR Medical to co-develop and commercialize the MINIject implant to treat patients with primary open-angle glaucoma. The device is already approved and marketed in Europe, and clinical trials are ongoing in the United States. iSTAR Medical will receive an upfront payment of $60 million from AbbVie, and after the U.S. trials are completed, AbbVie will have the exclusive right to acquire iSTAR Medical for $475, including contingent payments.